Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans for its dedicated oncology division in front of investors, aiming to add eight new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback